2007 publications

- Rizo A, Dontje B, Vellenga E, de Haan G, Schuringa JJ. Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. Blood. 2007 Dec 21 [Epub ahead of print]

- Gwenny M. Fuhler, A. Lyndsay Drayer, Jan J. Schuringa, Paul J. Coffer, Edo Vellenga, Reduced activation of protein kinase B, Rac and F-actin polymerisation contribute to an impairment of SDF-1-induced migration of CD34+ cells from patients with Myelodysplasia Blood. 2007 Sep 26; [Epub ahead of print]

- Hein Schepers, Djoke van Gosliga, Albertus T. J. Wierenga, Bart J. L. Eggen, Jan Jacob Schuringa, Edo Vellenga. Stat5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 2007, 110(8):2880-8.

^- Hein Schepers, Albertus T. J. Wierenga, Djoke van Gosliga, Bart J. L. Eggen, Edo Vellenga, Jan Jacob Schuringa. Re-introduction of C/EBPa in leukemic CD34⁺ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood 2007, 110(4):1317-25.

- Djoke van Gosliga, Hein Schepers, Aleksandra Rizo, Dorina van der Kolk, Edo Vellenga, and Jan Jacob Schuringa. Establishing long-term cultures with self-renewing Acute Myeloid Leukemia stem /progenitor cells. Exp.Hematology 2007, 35(10):1538-49.

 - Marjan Rozenveld-Geugien, Inge Baas, Djoke van Gosliga, Edo Vellenga, and Jan Jacob Schuringa. Rac-mediated interaction with stroma is required for the expansion of human hematopoietic stem and progenitor cells. Exp Hematol. 2007, 35(5):782-92.
- Moore MA, Chung KY, Plasilova M, Schuringa JJ, Shieh JH, Zhou P, Morrone G. NUP98 dysregulation in myeloid leukemogenesis. Ann N Y Acad Sci. 2007 Apr 18; [Epub ahead of print]

- Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp Hematol. 2007 Apr;35:105-16.

- Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch cooperative group HOVON 24 trial. Haematologica. 2007 Jul;92(7):928-35.

-  Daenen S, van Imhoff GW, de Wolf JT, Vellenga E, van den Berg-de Ruiter E, Kluin-Nelemans HC. A 'pre-induction course' with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia. Br J Haematol. 2007 Jul;138(2):275-7.

-  Heijink IH, Kies PM, Kauffman HF, Postma DS, van Oosterhout AJ, Vellenga E. Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity. J Immunol. 2007 Jun 15;178(12):7678-85.

- Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, Te Meerman GJ, Niens M, Nolte IM, Bastiaannet E, Schaapveld M, Vellenga E, Poppema S. HLA Class II Expression by Hodgkin's Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma. J Clin Oncol. 2007 May 29; [Epub ahead of print]

- Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Vellenga E, Haagsma EB, Posthumus MD, Jager PL.  Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med. 2007 Jun;48(6):865-72.

  - de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E . ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol. 2007 Mar 14 [Epub ahead of print] 
- van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, Vellenga E, Ossenkoppele GJ, Lowenberg B, Sonneveld P . CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007 May;86(5):329-37.

- Fuhler GM, Blom NR, Coffer PJ, Drayer AL, Vellenga E. The reduced GM-CSF priming of ROS production in granulocytes from patients with myelodysplasia is associated with an impaired lipid raft formation. J Leukoc Biol. 2007 Feb;81(2):449-57.